Search

Background: Major depressive disorder (MDD) in young patients represents a real public health problem, with a concerning increase in its prevalence. Aim of the study: To observe and to document relevant information regarding the particularities and the evolutive clinical patterns of MDD in young patients (18–50 years). Material and methods: We conducted a retrospective cross-sectional descriptive study on 68 patients diagnosed with MDD, aged 18–50 years, admitted to the First Department of Psychiatry of the Clinical County Hospital of Târgu Mureș, Romania between January 1, 2019 and September 30, 2020. Data regarding the patients’ psychiatric evaluation (primary and secondary diagnosis, relapses, associated personality disorders, autolytic attempts, treatment options, evolution, comorbidities) and psychological evaluation (HAM-D, HAM-A, GAF) were analyzed. Results: The highest prevalence of MDD was found in the 41–50 years age group (66%), followed by the 31–40 years age group (24%). Regarding the GAF and HAM-D scales, 90% of patients had scores in the range of 41–50 and >20 respectively. We found a high prevalence of personality disorders (75%), the most common being borderline personality disorder (27%). Younger patients (18–35 years) tended to recover quicker, with an average of 8.15 hospitalization days compared to older patients (36–50 years) who had an average of 12 days. Relapses were present in 55% of cases, being more frequent in women, and there was a 50% rate of relapse in subjects with no social support network. Autolytic attempts were present in 25% of cases and insomnia in 92%. Conclusions: MDD has a major impact on the patients’ global functionality and their quality of life. In our study, women were more vulnerable to develop MDD, while younger adults were less prone to develop MDD and they recovered more quickly.

Schizophrenic patients have a life expectancy shorter than that of the general population. The multisystemic implication of the psychotic disease is evidenced by the high prevalence of somatic comorbidities associated with the illness. Patients with schizophrenia have a higher risk to develop somatic comorbidities due to their lifestyle changes, medication intake and poor medical assistance. We conducted a retrospective descriptive study in order to determine the prevalence of certain somatic conditions associated with schizophrenia as well as the characteristics of this particular group of patients.

Background: Bioresonance therapy is a holistic physical method used in the treatment of various diseases. Aim of the study: The aim of the present paper was to evaluate the effect of bioresonance therapy in patients with recurrent major depressive disorder and with mild or moderate depressive episodes, respectively, without any other pharmacological, psychological, or other type of treatment. Methods: We selected 40 patients diagnosed with recurrent depressive disorder and bioresonance therapy as the only treatment. Assessment of the level of depression was achieved by measuring the biorhythm with the bioresonance device and by applying the Hamilton Depression Inventory questionnaire, with 17 items, at the beginning and the end of five weeks of treatment. Results: We identified a statistically significant decrease in depression levels as quantified by the HAM-D 17 scale, between the initial and final phase of therapy (p = 0.0001). Conclusions: Our results suggest that bioresonance therapy can decrease the level of depression in patients with recurrent depressive disorder, with mild and moderate depressive episodes.

The aim of the study was to evaluate if bioresonance therapy can offer quantifiable results in patients with recurrent major depressive disorder and with mild, moderate, or severe depressive episodes by decreasing the level of depression due to the application of bioresonance therapy as independently or complementary treatment. The study included 140 patients suffering from depression, divided into three groups. The first group (40 patients) received solely bioresonance therapy, the second group (40 patients) received pharmacological treatment with antidepressants combined with bioresonance therapy, and the third group (60 patients) received solely pharmacological treatment with antidepressants. The assessment of depression was made using the Hamilton Depression Rating Scale, with 17 items, at the beginning of the bioresonance treatment and the end of the five weeks of treatment, aiming to decrease the level of depression. The study identified the existence of a statistically significant difference for the treatment methods applied to the analyzed groups (p=0.0001), and we found that the therapy accelerates the healing process in patients with depressive disorders. Improvement was observed for the analyzed groups, with a decrease of the mean values between the initial and final phase of the level of depression, of delta for Hamilton score of 3.1, 3.8 and 2.3, respectively. We concluded that the bioresonance therapy could be useful in the treatment of recurrent major depressive disorder with moderate depressive episodes independently or as a complementary therapy to antidepressants.

The presenile dermatozoic delusion, subsequently referred to as Ekbom's syndrome and delusional parasitosis is a rare chronic condition, having an undetermined etiology and rising challenging treatment approaches. The diagnosis of delusional parasitosis can be presumed on the basis of the clinical history, but it is important to thoroughly assess the existence of an underlying systemic disorder or unrecognized skin disorder. A skin examination must be performed to rule out an infestation or a skin disorder. We present a 63-year-old diabetic woman with a high level of resilience towards the psychiatric treatment for whom we successfully offered outpatient psychiatric and dermatological assistance during the pandemic COVID-19. The trigger for a successful treatment scheme in outpatient care in a case of delusional parasitosis was the close and trustful relationship between the patient and the doctor. Different pharmacological treatments were approached and adjusted according to the patient adherence and the objective result (quetiapine XR, duloxetine, risperidone, olanzapine, and lamotrigine along with chronic disease treatment and wound management). Having a mutual agreed objective criteria for the treatment outcome, and creating a throughout examination scheme with frequent medical checks, increased the patient adherence to the treatment.

Depression is a negative emotional state that may persist for short or long periods of time with varying severity. The aim of the present study was to evaluate the method by which bioresonance therapy can improve the severity of recurrent depressive disorder with moderate and mild episodes experienced by patients. Bioresonance therapy is a method of energy treatment that processes the electromagnetic information of the human body using a sensitive Mora Nova device using electrodes. In addition, this improvement was compared with the one obtained by applying monotherapy with selective serotonin reuptake inhibitors. The study included two groups of patients suffering from depression. The first group received bioresonance treatment for five weeks. The second group received either newly introduced or on-going pharmacological treatment with selective serotonin reuptake inhibitor antidepressants, as monotherapy, for five weeks. An outcome measurement of severity was performed. Results revealed that, the score improvement on the Hamilton Scale, used for assessing depression and comprising 17 items, showed a mean of 3.1 [standard deviation (SD), 1.28] for the bioresonance group one and a mean of 2.2 (SD, 0.61) for the second group. The difference between the two data series was statistically significant (P0.0001, Student's t-test). As the bioresonance therapy outcome was higher than the selective serotonin reuptake inhibitor medication outcome, it can be concluded that bioresonance can reduce the severity of the patients facing recurrent depressive disorder with moderate and mild episodes. Furthermore, the reduction in severity for the bioresonance group compared with the antidepressant medication group was statistically significant.